Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma.

Parmar G, Capra M, Hungria V, Seguro FS, Dimopoulos MA, Delimpasi S, Špička I, Minařík J, Marques H, Pour L, Mihályová J, Yuda J, Sunami K, Esteves G, Chmielewski C, Soufflet C, Yu D, Comerford E, Suzan F, Cordero P, Zhang R, Quach H

Open source

DOI: 10.1016/j.clml.2026.08.019
Published: 2026 Sep 3
Container: Clinical lymphoma, myeloma & leukemia
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.clml.2026.08.019,
  title = {Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma.},
  author = {Parmar G and Capra M and Hungria V and Seguro FS and Dimopoulos MA and Delimpasi S and Špička I and Minařík J and Marques H and Pour L and Mihályová J and Yuda J and Sunami K and Esteves G and Chmielewski C and Soufflet C and Yu D and Comerford E and Suzan F and Cordero P and Zhang R and Quach H},
  year = {2026},
  journal = {Clinical lymphoma, myeloma \& leukemia},
  doi = {10.1016/j.clml.2026.08.019},
  url = {https://doi.org/10.1016/j.clml.2026.08.019}
}

RIS

TY  - JOUR
TI  - Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma.
AU  - Parmar G
AU  - Capra M
AU  - Hungria V
AU  - Seguro FS
AU  - Dimopoulos MA
AU  - Delimpasi S
AU  - Špička I
AU  - Minařík J
AU  - Marques H
AU  - Pour L
AU  - Mihályová J
AU  - Yuda J
AU  - Sunami K
AU  - Esteves G
AU  - Chmielewski C
AU  - Soufflet C
AU  - Yu D
AU  - Comerford E
AU  - Suzan F
AU  - Cordero P
AU  - Zhang R
AU  - Quach H
PY  - 2026
JO  - Clinical lymphoma, myeloma & leukemia
DO  - 10.1016/j.clml.2026.08.019
UR  - https://doi.org/10.1016/j.clml.2026.08.019
ER  -

APA

G, P., M, C., V, H., FS, S., MA, D., S, D., I, Š., J, M., H, M., L, P., J, M., J, Y., K, S., G, E., C, C., C, S., D, Y., E, C., F, S., P, C., R, Z., & H, Q. (2026). Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2026.08.019

Source records

pubmed · retrieved 2026-09-26T12:23:54.626Z